Información para prescribir Hepa-Merz® (F.F Granulado) Reg. No. 243M2000 SSA IV
Información para prescribir Hepa-Merz® (F.F solución (Inyectable)) Reg. No. 215M2000 SSA IV
Higuera-de-la-tijera F, Velasco JAV, Ra RH. Visión actual sobre el diagnóstico y los cuidados integrales en la encefalopatía hepática. Rev Gastroenterol Mex. 2023
Kircheis G, Lüth S. Pharmacokinetic and Pharmacodynamic Properties of l-Ornithine l-Aspartate (LOLA) in Hepatic Encephalopathy. Drugs 2019;79(s1):23–9
Butterworth RF. Ammonia Removal by Metabolic Scavengers for the Prevention and Treatment of Hepatic Encephalopathy in Cirrhosis. Drugs R D 2021;21(2):123–32
Butterworth RF, Gruengreiff K. L-Ornithine L-Aspartate (LOLA) for the Treatment of Hepatic Encephalopathy in Cirrhosis: Evidence for Novel Hepatoprotective Mechanisms.J Liver Clin Res 2018;5(1):1044
Butterworth RF, Canbay A. Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease. Dig Dis 2018;37(1):63–8
Butterworth RF. Beneficial effects of L-ornithine L-aspartate for prevention of overt hepatic encephalopathy in patients with cirrhosis: a systematic review with meta-analysis. Metab Brain Dis 2020;35:75–81 hepatitis C at the pre-cirrhotic stage. Ter Arkh 2019;91(2):52–8
Moreno-Cobos A, Higera-de la Tijera F, Hinojosa-Segura C, Montemira-Orozco D. Short-term efficacy and safety of l-ornithine l- aspartate therapy in patients with cirrhosis and minimal hepaticencephalopathy: a real-life cohort study. Ann Hepatol 2022;27(100782):1665–2681
Alvares-da-Silva MR, de Araujo A, Vicenzi JR, da Silva GV, Oliveira FB, Schacher F, et al. Oral l-ornithine-l-aspartate in minimal hepatic encephalopathy: A randomized, double-blind, placebo-controlled trial. Hepatol Res 2014;44(9):956–63
Jain A, Sharma BC, Mahajan B, Srivastava S, Kumar A, Sachdeva S, et al. L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial. Hepatology 2022;75(5):1194–203
Ong JP, Oehler G, Krüger-Jansen C, Lambert-Baumann J, Younossi ZM. Oral L-Ornithine-L-Aspartate Improves Health-Related Quality of Life in Cirrhotic Patients with Hepatic Encephalopathy. Clin Drug Investig 2011;31(4):213–20
Abdo-Francis JM, Pérez-Hernández JL, Hinojosa-Ruiz A, Hernández-Vásquez JR. Disminución de la estancia hospitalaria con el uso de L-ornitina L-aspartato (LOLA) en pacientes con encefalopatíahepática. Rev Gastroenterol Mex 2010;75(2):135–41
Buyeverov AO, Bogomolov PO, Mayev I V, Matsievich M V, Uvarova O V. Possibilities of therapeutic correction of hyperammonemia and minimal hepatic encephalopathy in patients with chronic hepatitis C at the pre-cirrhotic stage. Ter Arkh 2019;91(2):52–8
Vilstrup H, Amodio P, Bajaj J, et al. Hepatic Encephalopathy in Chronic Liver Disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60:715-